Witnessing the stock’s movement on the chart, on Wednesday, Arbutus Biopharma Corp (NASDAQ: ABUS) set off with pace as it heaved 0.74% to $4.06, before settling in for the price of $4.03 at the close. Taking a more long-term approach, ABUS posted a 52-week range of $1.69-$4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 55.33% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 18.41%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 12.27%. This publicly-traded company’s shares outstanding now amounts to $169.87 million, simultaneously with a float of $146.67 million. The organization now has a market capitalization sitting at $766.45 million. At the time of writing, stock’s 50-day Moving Average stood at $4.01, while the 200-day Moving Average is $3.23.
Arbutus Biopharma Corp (ABUS) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Arbutus Biopharma Corp’s current insider ownership accounts for 22.31%, in contrast to 51.24% institutional ownership. According to the most recent insider trade that took place on Aug 14 ’24, this organization’s Director sold 8,846 shares at the rate of 3.69, making the entire transaction reach 32,637 in total value, affecting insider ownership by 46,069. Preceding that transaction, on Feb 02 ’24, Company’s Chief Medical Officer sold 4,358 for 2.31, making the whole transaction’s value amount to 10,078. This particular insider is now the holder of 125,542 in total.
Arbutus Biopharma Corp (ABUS) Earnings and Revenue Records
Arbutus Biopharma Corp’s EPS increase for this current 12-month fiscal period is 12.27% and is forecasted to reach -0.35 in the upcoming year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arbutus Biopharma Corp (ABUS). It’s Quick Ratio in the last reported quarter now stands at 6.56. The Stock has managed to achieve an average true range (ATR) of 0.15. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 76.19.
In the same vein, ABUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.44, a figure that is expected to reach -0.09 in the next quarter, and analysts are predicting that it will be -0.35 at the market close of one year from today.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Going through the that latest performance of [Arbutus Biopharma Corp, ABUS]. Its last 5-days volume of 0.89 million was inferior to the volume of 1.14 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 52.96% While, its Average True Range was 0.15.
Raw Stochastic average of Arbutus Biopharma Corp (ABUS) in the period of the previous 100 days is set at 63.26%, which indicates a major rise in contrast to 56.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 34.83% that was lower than 42.75% volatility it exhibited in the past 100-days period.
